Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ariad and Medinol Strike Stent Accord - Medical Product Outsourcing

Ariad and Medinol Strike Stent Accord

Cambridge, MA-based Ariad Pharmaceuticals will provide Israel-based Medinol, a cardiac stent maker, its cancer drug candidate for use in Medinol drug-coated stents in a deal that could be worth $39 million plus royalty payments.

According to the agreement, Ariad will supply to Medinol its AP23573, which is currently in clinical trials. Medinol will be responsible for the development and commercialization of the medical devices.

Medinol may face an uphill battle in commercializing its product. It is currently involved in a lawsuit with a former partner, Natick, MA-based Boston Scientific, the coronary drug stent market leader. Medinol has charged that Boston Scientific secretly set up a factory in Ireland to manufacture the Medinol stents without its permission. A federal district court in New York City ruled last December that the case, in which Medinol claims Boston Scientific is guilty of breach of contract, can go forward. Medinol is seeking royalties on the sales of the Taxus Express stents.

Add us as a preferred source on Google

Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters